PMID- 35177990
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220219
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Potentially Hazardous Drug-Drug Interactions Associated With Oral Antineoplastic 
      Agents Prescribed in Chinese Tertiary Care Teaching Hospital Settings: A 
      Multicenter Cross-Sectional Study.
PG  - 808848
LID - 10.3389/fphar.2022.808848 [doi]
LID - 808848
AB  - Background: Oral administration increases the risk of interactions, because most 
      oral antineoplastic agents (OAAs) are taken on a daily basis. Interactions can 
      increase exposure to antitumoral agents or cause treatment failure. Potential 
      drug-drug interactions (DDIs) are commonly observed in patients with cancer, 
      while the extent to which OAAs related hazardous DDIs remains unclear. Methods: 
      We studied the contraindication patterns between oral antineoplastic agents and 
      other medications among cancer patients in two tertiary care teaching hospitals 
      in China. A total of 20 clinically significant hazardous DDI pairs that involved 
      30 OAAs were identified based on the predetermined criteria. Patient medications 
      were checked for DDIs by using the US Food and Drug Administration approved 
      labeling. Descriptive statistics and uni- and multivariate logistic regression 
      analyses were carried out. Results: In this study, 13,917 patients were included 
      and a total of 297 DDIs were identified. The results revealed that proton pump 
      inhibitors (PPIs), dexamethasone and fluoroquinolones were the most often 
      involved hazardous DDIs with OAAs. The most prevalent contraindication is the 
      simultaneous use of certain molecular targeted agents and PPIs. In the result of 
      the multivariate analysis, younger age (0-20 group), increasing number of drugs 
      and patient treated with targeted therapy had a higher risk for DDIs. Conclusion: 
      The prevalence of OAAs related hazardous DDIs appears to be low in the cancer 
      patients. However, physicians and clinical pharmacologists should be aware of the 
      potential hazardous DDIs when prescribing OAAs, especially certain pH-dependent 
      molecular targeted agents and potential QTc prolonging drugs.
CI  - Copyright (c) 2022 Wang, Shi, Wang, Wang, Li, Yang, Li, Liu, Zan, Feng and Xie.
FAU - Wang, Haitao
AU  - Wang H
AD  - Department of Pharmacy, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Shi, Haitao
AU  - Shi H
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Wang, Yan
AU  - Wang Y
AD  - Department of Pharmacy, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Wang, Na
AU  - Wang N
AD  - Department of Pharmacy, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Li, Youjia
AU  - Li Y
AD  - Department of Pharmacy, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Yang, Qianting
AU  - Yang Q
AD  - Department of Pharmacy, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Li, Ya
AU  - Li Y
AD  - Department of Pharmacy, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Liu, Chenwei
AU  - Liu C
AD  - Department of Pharmacy, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Zan, Ying
AU  - Zan Y
AD  - Department of Medical Oncology, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Feng, Siping
AU  - Feng S
AD  - Department of Pharmacy, Yan'an People's Hospital, Yan'an, China.
FAU - Xie, Jiao
AU  - Xie J
AD  - Department of Pharmacy, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
LA  - eng
PT  - Journal Article
DEP - 20220201
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8844504
OTO - NOTNLM
OT  - adverse drug events (ADE)
OT  - cancer
OT  - drug-drug interaction (DDI)
OT  - oral antineoplastic agents
OT  - prevalence
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/02/19 06:00
MHDA- 2022/02/19 06:01
PMCR- 2022/02/01
CRDT- 2022/02/18 05:47
PHST- 2021/11/04 00:00 [received]
PHST- 2022/01/10 00:00 [accepted]
PHST- 2022/02/18 05:47 [entrez]
PHST- 2022/02/19 06:00 [pubmed]
PHST- 2022/02/19 06:01 [medline]
PHST- 2022/02/01 00:00 [pmc-release]
AID - 808848 [pii]
AID - 10.3389/fphar.2022.808848 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Feb 1;13:808848. doi: 10.3389/fphar.2022.808848. 
      eCollection 2022.